IBRX - ImmunityBio, Inc.
2.07
-0.020 -0.966%
Share volume: 6,528,774
Last Updated: 05-09-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.03%
PREVIOUS CLOSE
CHG
CHG%
$2.09
-0.02
-0.01%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
| Report Date | 05-11-2023 | 08-08-2023 | 11-09-2023 | 03-19-2024 | 05-09-2024 | 08-12-2024 | 11-12-2024 | 03-03-2025 | |
| Assets | |||||||||
| Total Assets | 343.400 M | 291.227 M | 432.419 M | 504.452 M | 400.679 M | 444.325 M | 364.570 M | 382.933 M | |
| Current Assets | 113.486 M | 66.825 M | 215.082 M | 294.084 M | 195.722 M | 242.830 M | 163.150 M | 184.586 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 1.811 M | 1.958 M | 8.272 M | |
| Other Current Assets | 20.754 M | 18.846 M | 22.961 M | 25.603 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 20.754 M | 18.846 M | 22.961 M | 25.603 M | 37.460 M | 87.875 M | 18.401 M | 6.381 M | |
| Total Receivables | 1.464 M | 2.025 M | 2.325 M | 2.019 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 91.268 M | 45.954 M | 189.796 M | 266.462 M | 133.035 M | 130.104 M | 111.966 M | 143.428 M | |
| Total Non-current Assets | 229.914 M | 224.402 M | 217.337 M | 210.368 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 154.165 M | 151.487 M | 152.000 M | 146.082 M | 143.517 M | 141.956 M | 139.285 M | 137.094 M | |
| Other Assets | 55.427 M | 53.082 M | 46.053 M | 46.302 M | 61.440 M | 59.539 M | 62.135 M | 61.253 M | |
| Intangible Assets | 19.502 M | 18.992 M | 18.467 M | 17.093 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 343.400 M | 291.227 M | 432.419 M | 504.452 M | 400.679 M | 444.325 M | 364.570 M | 382.933 M | |
| Total liabilities | 872.383 M | 933.343 M | 844.136 M | 1.091 B | 1.092 B | 1.142 B | 1.109 B | 871.062 M | |
| Total current liabilities | 564.945 M | 613.478 M | 90.324 M | 58.283 M | 53.759 M | 62.110 M | 60.960 M | 54.944 M | |
| Accounts Payable | 33.573 M | 25.488 M | 21.090 M | 10.331 M | 47.677 M | 55.861 M | 53.927 M | 47.478 M | |
| Other liabilities | 18.242 M | 28.272 M | 39.837 M | 415.213 M | 187.401 M | 123.333 M | 74.997 M | 531.714 M | |
| Current long term debt | 474.322 M | 524.496 M | 4.363 M | 5.244 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 291.929 M | 294.660 M | 712.903 M | 616.893 M | 850.502 M | 956.260 M | 972.775 M | 284.404 M | |
| Other liabilities | 18.242 M | 28.272 M | 39.837 M | 415.213 M | 187.401 M | 123.333 M | 74.997 M | 531.714 M | |
| Minority interest | -2.733 M | -3.067 M | 1.072 M | 1.050 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -528.983 M | -642.116 M | -411.717 M | -586.987 M | -692.012 M | -698.387 M | -745.148 M | -489.098 M | |
| Common stock | 428.381 M | 437.457 M | 498.375 M | 670.329 M | 2.404 B | 2.532 B | 2.571 B | 2.885 B | |
| Retained earnings | -2.495 B | -2.633 B | -2.728 B | -2.962 B | -3.096 B | -3.230 B | -3.316 B | -3.375 B |
